Based on our expertise and interest in CRC, weaimed to perform in vivo validation using the murineCRC model CT26, which is well-characterized for its high albumin uptakeand favorable response to albumin-bound prodrugs. CT26 was injected not only subcutaneously into mice butalso in form of an orthotopic carcinosis model to demonstrate thatthe strategy is effective beyond subcutaneous tumors, which exhibita pronounced EPR effect. This evidence concerns the gene ALB and colorectal carcinoma.